Miss Laura Divers
- Affiliate -Clinical Trials Unit (School of Cancer Sciences)
email:
Laura.Divers@glasgow.ac.uk
Coap, Alexander Stone Building, Alexander Stone Building
The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Hotjar and Clarity help us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
email:
Laura.Divers@glasgow.ac.uk
Coap, Alexander Stone Building, Alexander Stone Building
Edmondson, R. J. et al. (2021) Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology, 163(3), pp. 524-530. (doi: 10.1016/j.ygyno.2021.09.010) (PMID:34625284)
Friedlander, M. et al. (2021) Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology, 161(1), pp. 160-165. (doi: 10.1016/j.ygyno.2021.02.016) (PMID:33608144)
Edmondson, R. J. et al. (2021) Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology, 163(3), pp. 524-530. (doi: 10.1016/j.ygyno.2021.09.010) (PMID:34625284)
Friedlander, M. et al. (2021) Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903). Gynecologic Oncology, 161(1), pp. 160-165. (doi: 10.1016/j.ygyno.2021.02.016) (PMID:33608144)